William H Shrank

Summary

Country: USA

Publications

  1. ncbi request reprint A bitter pill: formulary variability and the challenge to prescribing physicians
    William H Shrank
    Division of General Internal Medicine, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA
    J Am Board Fam Pract 17:401-7. 2004
  2. ncbi request reprint Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey
    William H Shrank
    Division of General Internal Medicine, VA Greater Los Angeles Health Care System, Los Angeles, Calif 90073, USA
    Am J Manag Care 11:16-22. 2005
  3. pmc Focus group findings about the influence of culture on communication preferences in end-of-life care
    William H Shrank
    Division of General Internal Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    J Gen Intern Med 20:703-9. 2005
  4. doi request reprint Patient, physician, and payment predictors of statin adherence
    David C Chan
    Department of Medicine, Division of General Internal Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Med Care 48:196-202. 2010
  5. pmc Fostering professionalism in medical education: a call for improved assessment and meaningful incentives
    William H Shrank
    VA Greater Los Angeles Healthcare System, CA 90073, USA
    J Gen Intern Med 19:887-92. 2004
  6. ncbi request reprint A practical physicians' guide to the Medicare drug benefit plan
    Alex D Federman
    Division of General Internal Medicine, Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York 10029, USA
    Mayo Clin Proc 81:1217-21. 2006
  7. pmc Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am Heart J 156:31-6. 2008
  8. ncbi request reprint Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007
  9. ncbi request reprint Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Ste 3030, Boston, MA 02120, USA
    Am J Manag Care 12:545-51. 2006
  10. pmc The effect of pharmacy benefit design on patient-physician communication about costs
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Gen Intern Med 21:334-9. 2006

Detail Information

Publications17

  1. ncbi request reprint A bitter pill: formulary variability and the challenge to prescribing physicians
    William H Shrank
    Division of General Internal Medicine, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA
    J Am Board Fam Pract 17:401-7. 2004
    ..However, the degree of formulary variability among and within health plans over time is unclear...
  2. ncbi request reprint Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey
    William H Shrank
    Division of General Internal Medicine, VA Greater Los Angeles Health Care System, Los Angeles, Calif 90073, USA
    Am J Manag Care 11:16-22. 2005
    ..Three-tier pharmaceutical benefit systems use graded co-payments to steer patients toward "preferred" formulary medications...
  3. pmc Focus group findings about the influence of culture on communication preferences in end-of-life care
    William H Shrank
    Division of General Internal Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    J Gen Intern Med 20:703-9. 2005
    ..Little guidance is available for health care providers who try to communicate with patients and their families in a culturally sensitive way about end-of-life care...
  4. doi request reprint Patient, physician, and payment predictors of statin adherence
    David C Chan
    Department of Medicine, Division of General Internal Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Med Care 48:196-202. 2010
    ..Although many patient, physician, and payment predictors of adherence have been described, knowledge of their relative strength and overall ability to explain adherence is limited...
  5. pmc Fostering professionalism in medical education: a call for improved assessment and meaningful incentives
    William H Shrank
    VA Greater Los Angeles Healthcare System, CA 90073, USA
    J Gen Intern Med 19:887-92. 2004
    ..The third-year medicine clerkship provides an ideal opportunity for clinician-educators to play a leading role in evaluating, rewarding, and ultimately fostering professionalism in medical school graduates...
  6. ncbi request reprint A practical physicians' guide to the Medicare drug benefit plan
    Alex D Federman
    Division of General Internal Medicine, Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York 10029, USA
    Mayo Clin Proc 81:1217-21. 2006
    ..This may, in turn, reduce beneficiaries' out-of-pocket prescription costs, thereby improving patients' access to medications and possibly their medication adherence and health outcomes as well...
  7. pmc Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am Heart J 156:31-6. 2008
    ..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective...
  8. ncbi request reprint Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis
    Niteesh K Choudhry
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    Health Aff (Millwood) 26:186-94. 2007
    ..Our analysis suggests that covering combination therapy for such patients will save both lives and money...
  9. ncbi request reprint Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Ste 3030, Boston, MA 02120, USA
    Am J Manag Care 12:545-51. 2006
    ..We evaluated physicians' perceptions about relevant costs for prescription drugs and the importance of communication about these costs...
  10. pmc The effect of pharmacy benefit design on patient-physician communication about costs
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Gen Intern Med 21:334-9. 2006
    ..The impact of financial incentives on patient awareness of and communication about those costs is unknown...
  11. ncbi request reprint The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 166:332-7. 2006
    ..We studied whether patients enrolled in such plans who receive generic or preferred brand-name agents when initiating chronic therapy were more adherent to treatment than those who received nonpreferred brand-name medications...
  12. ncbi request reprint Effect of incentive-based formularies on drug utilization and spending
    William H Shrank
    N Engl J Med 350:1057. 2004
  13. ncbi request reprint Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120 1613, USA
    Ann Pharmacother 40:1534-40. 2006
    ..Most insurers in the US have implemented incentive-based formularies that rely on out-of-pocket costs to influence prescription drug utilization. Medicare Part D plans have broadly adopted such benefit designs...
  14. ncbi request reprint Increasing generic drug use in Medicare Part D: the role of government
    Herb Kohl
    United States Senator from Wisconsin, Majority Leader, U S Senate Special Committee on Aging, 2nd and C St, NE, 330 Hart Senate Office Building, United States Senate, Washington, DC 20510, USA
    J Am Geriatr Soc 55:1106-9. 2007
  15. pmc Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    J Gen Intern Med 22:1298-304. 2007
    ..Increased use of generic medications conserves insurer and patient financial resources and may increase patient adherence...
  16. ncbi request reprint Quality indicators for medication use in vulnerable elders
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Am Geriatr Soc 55:S373-82. 2007
  17. pmc Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries
    Niteesh K Choudhry
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Circulation 117:1261-8. 2008
    ....